Blade: Bypass | Handles: Ergonomic rubber-coated | Locking mechanism: Dial | Maintenance: Replacement parts available

Far and away, the most popular pair of all-purpose shears among experts are the F2 bypass pruners manufactured by Swiss company Felco. “A good gardener or horticulturist anywhere in the world is most likely going to have a pair of Felcos,” says Morrell. Felco pruners are popular for their durability and the very long lifespan you can expect from them (Morrell still has his original pair from 1985) and their versatility. NYBG’s School of Professional Horticulture gives a pair of F2s to every new student. There are less expensive pruners on the market, but the years of use you can expect from Felco F2s makes the investment worthwhile. “They’re a staple of every gardener’s toolbox,” says Rachel Burlington, curator of the International Rose Test Garden. “I never leave home without mine.”

Felco also sells a lefty version of the F2 and other styles, including the compact F6, better for smaller hands (both of which are below). I tested both the F2 and F6, and I’ve been using the F6 consistently for about a year. Although the pruners are a heavier-duty tool than I thought I’d need as an indoor gardener, I found myself reaching for them for everything — having a reliable pair of pruners in your arsenal makes you realize just how many things you can use them for. I’ve pruned dead monstera leaves and trimmed bundles of fresh flowers with quicker and cleaners cut than I’d get with scissors. I’ve also found them very useful for processing produce, from chopping off the fibrous tops of fennel bulbs to breaking down kale stems into compost-bin-friendly pieces.

Another reason Felco pruners are our top pick: The brand sells replacements for every part, neatly identified on a schematic on its website, from tiny screws to fresh blades. So far, I haven’t needed them — I haven’t even noticed any dulling from the blades — but it’s an important factor if you’re hoping to follow in Morrell’s footsteps and get a three-decade lifespan out of your pruners.

US stocks edged higher on Tuesday as renewed US-China trade talks entered their second day after an upbeat initial meeting.

The Dow Jones Industrial Average (^DJI) finished the day up around 0.2%, while the S&P 500 (^GSPC) rose about 0.5%. The tech-heavy Nasdaq Composite (^IXIC) climbed roughy 0.6%.

Both the S&P 500 and Nasdaq are now within striking distance of their all-time closing highs — 6,144.15 for the S&P (set on February 19, 2025) and 20,173.89 for the Nasdaq (set on December 16, 2024). Stocks have been buoyed by resilient corporate earnings, more positive growth forecasts, and optimism over potential tariff deals.

The mood remains cautious, however, as investors keep a close eye on the latest trade developments. While a deal on access to China’s rare earth minerals is the US’s priority, negotiators are navigating contentious issues that have fueled a rift between the two trading partners.

Any signs of progress will likely be greeted with relief by markets, given switchbacks in President Trump’s tariff policy and in US-China relations have fed uncertainty about risks to economic growth worldwide. On Monday, stocks on Wall Street edged higher after White House officials suggested discussions had been productive — though Trump himself cautioned that “China’s not easy.”

Read more: The latest on Trump’s tariffs

Chinese stocks slid suddenly on Tuesday before the meeting resumed, a bout of volatility that suggested investors aren’t confident of success. “The market is too sensitive,” Fu Shifeng, investment director at Cheng Zhou Investment, told Bloomberg. “People seem to be speculating that the talks didn’t go well.”

Meanwhile, a gauge of US small-business optimism came in higher in May — the first rise since September — amid the trade truce with China. But worries about Trump’s tax-and-spending megabill stoked uncertainty about the outlook, the NFIB survey found.

Investors are now counting down to the release of the May Consumer Price Index (CPI) report on Wednesday. The report will offer fresh insight into the state of inflation amid Trump’s evolving trade policy. Analysts expect to see that price pressures accelerated last month.

LIVE COVERAGE IS OVER

19 updates

Voyager’s lead clinical candidate is VY7523, a monoclonal antibody designed to target pathological tau (pTAU), a protein closely associated with the progression of Alzheimer’s disease. Intended for early-stage intervention, the therapy has shown encouraging preclinical results. In mouse models, its murine surrogate demonstrated high selectivity for abnormal tau while sparing healthy tau and delivered strong efficacy in the P301S seeding model, a benchmark in Alzheimer’s research. Voyager recently completed a Phase 1 single ascending dose (SAD) trial in healthy volunteers and has since launched a multiple ascending dose (MAD) trial in patients with early-stage AD. Topline SAD results were positive, showing that VY7523 was well tolerated across dose levels and achieved expected central nervous system exposure.

One company Oppenheimer is especially bullish on is Voyager Therapeutics, a clinical-stage biotech developing treatments for serious neurological diseases, including Alzheimer’s disease and Friedreich’s ataxia – both of which have limited therapeutic options.

We checked in with the TipRanks database to see how the rest of Wall Street views these names. The verdict? Both picks carry Strong Buy consensus ratings across the board, with substantial upside potential. Let’s take a closer look at the details.

Against this backdrop, Oppenheimer analyst Jay Olson has picked out his winners for the months ahead, zeroing in on two stocks in particular – including one with the potential to jump ~550% by this time next year.

“The effects of the stock market rally from the lows seen on April 8 appear to us to augur positively for investors practicing diversification and patience notwithstanding near-term uncertainties… We remain overweight US equities and do not ascribe to the view that US exceptionalism is fading,” Stoltzfus noted.

Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term.

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited demand for risk assets, triggering the market’s biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year.

Story Continues

Alongside its antibody-based approach, Voyager is also advancing a gene therapy pipeline powered by its proprietary TRACER capsid technology. These engineered capsids are designed to deliver therapeutic payloads directly to brain cells while minimizing off-target exposure in tissues such as the liver. Among these programs is VY1706, a tau-silencing gene therapy intended to suppress pTAU production in neurons for the treatment of Alzheimer’s. At the 2025 AD/PD conference, Voyager presented encouraging non-human primate data showing that a single intravenous dose of VY1706 achieved dose-dependent, robust reductions in MAPT mRNA and tau protein across critical brain regions. An Investigational New Drug (IND) filing remains on track for 2026.

The promise of Voyager’s TRACER platform has attracted major pharmaceutical partners. Through deals with Neurocrine Biosciences, Novartis, and Alexion (a subsidiary of AstraZeneca), the company could earn up to $7.4 billion in milestone payments. The Neurocrine collaboration is already advancing gene therapy programs for Friedreich’s ataxia and GBA1-related disorders, with IND filings expected in 2025 and clinical trials slated to begin in 2026. Voyager could receive up to $35 million in milestone payments tied to these near-term milestones.

Currently trading at $2.74 per share, VYGR may be flying under the radar – but Oppenheimer’s Jay Olson sees it as a compelling entry point.

“We remain enthusiastic about VYGR’s unique platform and optionality, and believe VYGR is well-positioned to pursue tau-targeting with different approaches. VYGR’s strong balance sheet with a cash runway into mid-2027 should offer stability… Additionally, we are encouraged by the positive preclinical data, external validation of the platform technology through multiple collaborations with industry leaders, a strong management team, and our optimistic long-term view on the gene therapy and CNS therapeutic area,” Olson said.

To this end, Olson rates VYGR an Outperform (i.e., Buy), and his $18 price target implies room for a stunning 556% upside potential in the next 12 months. (To watch Olson’s track record, click here)

Olson’s view is highly bullish, to be sure, but so is the general Street take here. VYGR shares have a Strong Buy consensus rating, based on 10 unanimously positive recommendations. The average price target stands at $15, pointing to potential upside of 447% from current levels. (See VYGR stock forecast)

Tvardi Therapeutics (TVRD)

The second name catching Oppenheimer’s attention is Tvardi Therapeutics, another biopharmaceutical firm – but a newcomer to the public markets. The TVRD ticker began trading on the NASDAQ on April 16 of this year, following the completion of a merger between Tvardi Therapeutics and Cara Therapeutics.

Following its public debut, Tvardi is now focused on developing breakthrough therapies for fibrosis-driven diseases. Its approach centers on targeting STAT3 (signal transducer and activator of transcription 3), a key protein in the STAT family, known for its pivotal role in numerous cellular processes.

At the center of Tvardi’s clinical efforts is TTI-101, an oral small-molecule STAT3 inhibitor that selectively targets pY-STAT3 within the SH2 domain. Tvardi is advancing TTI-101 as a treatment for both hepatocellular carcinoma (HCC) and idiopathic pulmonary fibrosis (IPF), two diseases marked by high unmet need and limited effective therapies.

Early clinical results have been encouraging. In a first-in-human Phase 1 trial involving patients with advanced solid tumors, including HCC, TTI-101 was well tolerated with no dose-limiting toxicities. Pharmacodynamic data confirmed target engagement, with biopsies showing reduced levels of activated STAT3. Tvardi expects topline data from its ongoing Phase 1b/2 REVERT Liver Cancer clinical trial in HCC to be available in the first half of 2026.

Meanwhile, building on insights from the same trial, Tvardi is also advancing the REVERT IPF Phase 2 study – a randomized, double-blind, placebo-controlled trial evaluating TTI-101, both as a monotherapy and in combination with nintedanib, in patients diagnosed with IPF within the past seven years. On May 27, 2025, the company announced that enrollment was complete, with topline results expected in the fourth quarter of this year.

The potential of TTI-101, based on its earlier clinical trial results and optimistic forecasts for the current trials, has not gone unnoticed by Oppenheimer’s Olson. The analyst is encouraged by the possible long-term returns, assuming success in both the trial and regulatory process.

“We see an underappreciated opportunity for lead asset TTI-101 as we forecast ~$1.2B peak risk-adjusted sales in 2040. Blinded Ph2a interim data suggest that TTI-101 could reverse IPF progression, thus supporting favorable differentiation from key competitors, with detailed Ph2a results expected in 2H25 serving as a potential valuable inflection point. In HCC, we believe TTI-101 offers a novel, mechanistically distinct approach, with interim Ph1b/2 data suggesting synergy in combination with SoC ahead of topline results in 1H26. We leverage our expertise in IPF and HCC to inform our analysis, and view TVRD as well-capitalized through key catalysts… Based on our DCF valuation of TVRD, we believe that its shares remain underappreciated,” Olson stated.

With that backdrop, Olson rates TVRD an Outperform (i.e., Buy), alongside a $65 price target, suggesting a potential upside of 129% from current levels.

Overall, this new stock has picked up 4 analyst reviews since it went public, and all are positive – making the Strong Buy consensus rating unanimous. TVRD is currently trading for $28.34, and its $50.75 average price target suggests that the shares have a 79% upside lying in wait for the year ahead. (See TVRD stock forecast)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Disclaimer & DisclosureReport an Issue

US stocks moved higher on Thursday as markets assessed Nvidia’s (NVDA) earnings report as well as more tariff uncertainty.

In late afternoon trade, a federal appeals court allowed President Trump’s sweeping tariffs to temporarily stay in effect, a day after the US Court of International Trade blocked their implementation after deeming the method used to enact them “unlawful.”

That means Trump’s tariffs will remain in effect for now.

The benchmark S&P 500 (^GSPC) and tech-heavy Nasdaq Composite (^IXIC) closed up about 0.4% each, while the Dow Jones Industrial Average (^DJI) climbed around 0.3% as investors continue to debate Trump’s next move in trade policy. All three major averages had retreated from their highs of the day early in the session.

Nvidia stock rallied over 3% after its first quarter revenue topped estimates. Investors appear to be looking past the AI chipmaker’s warning that it expects to miss out on $8 billion in sales in the second quarter, thanks to US restrictions on exports to China.

Overall, Nvidia’s performance on Wednesday boosted hopes on Wall Street that Big Tech can weather Trump’s far-reaching trade policy.

Read more: The latest on Trump’s tariffs

Meanwhile, Best Buy (BBY) cut its full-year guidance citing economic uncertainty around those tariffs, sending its stock lower. Eyes are now on Costco’s (COST) after-hours report, given the difficult position retailers find themselves in: Trump told Walmart (WMT) to “eat” price hikes associated with new duties following its latest results.

On the economic front, filings for unemployment aid jumped more than expected last week. And in a slight upgrade from the initial reading, the Commerce Department said GDP shrank at a 0.2% annualized pace in the first quarter.

LIVE COVERAGE IS OVER

20 updates

Traditional diaper bags

We previously recommended the Hap Tim Diaper Bag Backpack as a minimally priced option, but we found the Ruvalino bag to be an improvement for about the same price. The Hap Tim backpack has padded straps and a padded back, but it ultimately felt bulky even when empty. Its 17 pockets can be too much — it was easy to lose things inside the bag.

We previously recommended the Skip Hop Mainframe Wide Open Diaper Backpack, a roomy bag with 10 pockets that can potentially hold items for multiple kids. It’s a reliable and affordable bag, but it appears to go in and out of stock.

We previously recommended the Babymel Robyn Convertible Backpack, which has a handy strap design that makes it easy to switch from backpack to shoulder or crossbody bag. But this bag is not as easy to clean as our other picks, and availability appears to be limited.

We previously recommended JuJuBe’s Be Right Back Diaper Backpack and the convertible BFF Diaper Bag, and we still think they’re great diaper bags. But they’re from JuJuBe’s older line, and they’ve become more limited in availability and color/pattern options.

The Dagne Dover Indi Neoprene Diaper Backpack is surprisingly comfortable to carry, despite weighing 3 to 4 pounds (depending on the size). We liked the gender-neutral design, high-quality materials, and roomy interior. However, with darker colors, the inside is made with a matching dark material, so it’s harder to see the pockets. It’s also not machine-washable.

The Tom Bihn Parental Unit is a sporty messenger-bag-style diaper bag that’s built to last. It’s made with rugged, waterproof nylon, plus heavy-duty components, like Duraflex buckles. The company also offers a lifetime guarantee against manufacturing defects. But this bag can quickly become heavy and unwieldy when packed.

The Herschel Supply Co. Strand Duffle Diaper Bag was the perfect bag for an overnight trip, but it felt overwhelming for everyday use. We tested the 29-liter tote in 2019; it has since been updated as a slightly smaller 24-liter bag, which we have not tested, but it has a similar design. The internal dividers make the bag tougher to clean; our bag continued to smell for a few days after we cleaned it.

The Petunia Pickle Bottom Boxy Backpack can convert into a backpack, messenger bag, or shoulder bag, though the straps are not padded. When we tested this in 2017, we especially liked the Boxy Backpack’s changing station: A cushioned changing pad folds out from the front of the backpack, revealing two elastic pockets that can hold diapers and wipes. With everything in one place, changing a squirmy, uncooperative baby’s diaper was very manageable. But this bag can’t go into the washing machine.

At 1 pound, the popular quilted Skip Hop Forma Backpack Diaper Bag is among the most lightweight bags we tried. However, when we filled it with baby paraphernalia, it didn’t distribute weight as comfortably as other backpacks.

The Tom Bihn Synapse 25 is not a dedicated diaper backpack, but some people have used it as such. With chest and waist straps to distribute weight, plus a padded back and straps, this bag is comfortable, albeit a bit large for a petite person to carry. There are no open side pockets for bottles. It has seven pockets, all of them zippered — not so convenient for parents who need to grab something quickly. This bag is relatively difficult to clean.

The Land diaper bag, which we tested in 2019 and is one of the least expensive bags we tested, was hailed as “the $30 answer to every parent’s needs” several years ago by The Strategist. We tested one version of it, the HaloVa, which is no longer available. But it comes in a variety of colors from several Amazon sellers, such as this one from Ticent, which we did not test. When we looked at it up-close, we thought the HaloVa didn’t look as nice as it did in the photos.

Because we looked for lighter-weight bags, we did not consider Fawn Design’s The Original Diaper Bag backpack, the Paperclip Willow, and the JJ Cole Satchel Diaper Bag. These bags weighed more than 3 pounds in 2019; they have since been updated to be about 3 pounds or less. We opted not to test them in 2024, since we found other comparably priced bags to be more appealing.

Fanny packs

We received compliments on the look of Tush Baby’s The Pack, but we weren’t fans of the external mesh water bottle pocket attached to the side. Although it didn’t tear during our testing, we were worried it would ultimately rip or snag after extended use. The elastic opening is also snug — it holds your bottle securely, but it’s challenging to slip a bottle in and out.

Freshly Picked’s Classic Park Pack is compact, stylish, and available in more than a dozen cute prints and colors. But we found it to be too compact for baby and toddler outings. It also doesn’t come with a changing pad; the separate Freshly Picked Changing Mat fits awkwardly in the bag.

Portable changing pads

The Momcozy Portable Diaper Changing Pad is similar in style to our pick, the Skip Hop Pronto, with a wipeable changing pad that folds out and pockets that hold diapers and wipes. But we found the design awkward: The wipes pocket is on the outside and must be detached and reattached when diapering. The two internal mesh pockets are also loosely secured by small hook-and-loop tabs, on which diapers can get easily caught.

The Momcozy 2-in-1 Diaper Changing Pad also folds out with a wipeable changing pad and has pockets for diapers and wipes. The wipes pocket for the 2-in-1 is more accessible than that on the Momcozy Portable Changing Pad, but the 2-in-1 has two hook-and-loop stroller straps (rather than a buckle like the Skip Hop Pronto), which were inconvenient to attach.

The Munchkin Go Change Portable Diaper Changing Kit is also similar in style to the Skip Hop Pronto, with a wipeable changing pad that folds out and two internal mesh pockets for diapers and wipes. We opted not to test it because we noticed that Munchkin’s detachable changing pad is held together with hook-and-loop tabs, rather than with a more-secure and easy-to-use zipper, like on the Skip Hop Pronto.

This article was edited by Amy Miller Kravetz, Ben Frumin, and Kalee Thompson.